Cargando…

miR-223-3p Inhibits Human Osteosarcoma Metastasis and Progression by Directly Targeting CDH6

Cadherin-6 (CDH6) is aberrantly expressed in cancer and closely associated with tumor progression. However, the functions of CDH6 in human osteosarcoma and the molecular mechanisms underlying CDH6 in osteosarcoma oncogenesis remain poorly understood. In this work, we assessed the role of CDH6 in hum...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Quanbo, Xu, Xiaojie, Song, Qi, Xu, Yameng, Tai, Yanhong, Goodman, Stuart B., Bi, Wenzhi, Xu, Meng, Jiao, Shunchang, Maloney, William J., Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993963/
https://www.ncbi.nlm.nih.gov/pubmed/29628305
http://dx.doi.org/10.1016/j.ymthe.2018.03.009
_version_ 1783330323886505984
author Ji, Quanbo
Xu, Xiaojie
Song, Qi
Xu, Yameng
Tai, Yanhong
Goodman, Stuart B.
Bi, Wenzhi
Xu, Meng
Jiao, Shunchang
Maloney, William J.
Wang, Yan
author_facet Ji, Quanbo
Xu, Xiaojie
Song, Qi
Xu, Yameng
Tai, Yanhong
Goodman, Stuart B.
Bi, Wenzhi
Xu, Meng
Jiao, Shunchang
Maloney, William J.
Wang, Yan
author_sort Ji, Quanbo
collection PubMed
description Cadherin-6 (CDH6) is aberrantly expressed in cancer and closely associated with tumor progression. However, the functions of CDH6 in human osteosarcoma and the molecular mechanisms underlying CDH6 in osteosarcoma oncogenesis remain poorly understood. In this work, we assessed the role of CDH6 in human osteosarcoma and identified that the expression of CDH6 was closely related with the overall survival and poor prognosis of osteosarcoma patients. MicroRNAs (miRNAs) have been implicated as important epigenetic regulators during the progression of osteosarcoma. Using dual-luciferase reporter assays, we showed that miR-223-3p suppresses CDH6 expression by directly binding to the 3′ UTR of CDH6. miR-223-3p overexpression significantly inhibited cell invasion, migration, growth, and proliferation by suppressing the CDH6 expression in vivo and in vitro. Besides, CDH6 overexpression in the miR-223-3p-transfected osteosarcoma cells effectively rescued the inhibition of cell invasion, migration, growth, and proliferation mediated by miR-223-3p. Additionally, Kaplan-Meier analysis suggests that the expression of miR-223-3p predicts favorable clinical outcomes for osteosarcoma patients. Moreover, the expression of miR-223-3p was downregulated in osteosarcoma patients and was negatively associated with the expression of CDH6. Collectively, these data highlight that miR-223-3p/CDH6 axis is an important novel pleiotropic regulator and could early predict the metastatic potential in human osteosarcoma treatments.
format Online
Article
Text
id pubmed-5993963
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher American Society of Gene & Cell Therapy
record_format MEDLINE/PubMed
spelling pubmed-59939632019-05-02 miR-223-3p Inhibits Human Osteosarcoma Metastasis and Progression by Directly Targeting CDH6 Ji, Quanbo Xu, Xiaojie Song, Qi Xu, Yameng Tai, Yanhong Goodman, Stuart B. Bi, Wenzhi Xu, Meng Jiao, Shunchang Maloney, William J. Wang, Yan Mol Ther Original Article Cadherin-6 (CDH6) is aberrantly expressed in cancer and closely associated with tumor progression. However, the functions of CDH6 in human osteosarcoma and the molecular mechanisms underlying CDH6 in osteosarcoma oncogenesis remain poorly understood. In this work, we assessed the role of CDH6 in human osteosarcoma and identified that the expression of CDH6 was closely related with the overall survival and poor prognosis of osteosarcoma patients. MicroRNAs (miRNAs) have been implicated as important epigenetic regulators during the progression of osteosarcoma. Using dual-luciferase reporter assays, we showed that miR-223-3p suppresses CDH6 expression by directly binding to the 3′ UTR of CDH6. miR-223-3p overexpression significantly inhibited cell invasion, migration, growth, and proliferation by suppressing the CDH6 expression in vivo and in vitro. Besides, CDH6 overexpression in the miR-223-3p-transfected osteosarcoma cells effectively rescued the inhibition of cell invasion, migration, growth, and proliferation mediated by miR-223-3p. Additionally, Kaplan-Meier analysis suggests that the expression of miR-223-3p predicts favorable clinical outcomes for osteosarcoma patients. Moreover, the expression of miR-223-3p was downregulated in osteosarcoma patients and was negatively associated with the expression of CDH6. Collectively, these data highlight that miR-223-3p/CDH6 axis is an important novel pleiotropic regulator and could early predict the metastatic potential in human osteosarcoma treatments. American Society of Gene & Cell Therapy 2018-05-02 2018-03-14 /pmc/articles/PMC5993963/ /pubmed/29628305 http://dx.doi.org/10.1016/j.ymthe.2018.03.009 Text en © 2018 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Ji, Quanbo
Xu, Xiaojie
Song, Qi
Xu, Yameng
Tai, Yanhong
Goodman, Stuart B.
Bi, Wenzhi
Xu, Meng
Jiao, Shunchang
Maloney, William J.
Wang, Yan
miR-223-3p Inhibits Human Osteosarcoma Metastasis and Progression by Directly Targeting CDH6
title miR-223-3p Inhibits Human Osteosarcoma Metastasis and Progression by Directly Targeting CDH6
title_full miR-223-3p Inhibits Human Osteosarcoma Metastasis and Progression by Directly Targeting CDH6
title_fullStr miR-223-3p Inhibits Human Osteosarcoma Metastasis and Progression by Directly Targeting CDH6
title_full_unstemmed miR-223-3p Inhibits Human Osteosarcoma Metastasis and Progression by Directly Targeting CDH6
title_short miR-223-3p Inhibits Human Osteosarcoma Metastasis and Progression by Directly Targeting CDH6
title_sort mir-223-3p inhibits human osteosarcoma metastasis and progression by directly targeting cdh6
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993963/
https://www.ncbi.nlm.nih.gov/pubmed/29628305
http://dx.doi.org/10.1016/j.ymthe.2018.03.009
work_keys_str_mv AT jiquanbo mir2233pinhibitshumanosteosarcomametastasisandprogressionbydirectlytargetingcdh6
AT xuxiaojie mir2233pinhibitshumanosteosarcomametastasisandprogressionbydirectlytargetingcdh6
AT songqi mir2233pinhibitshumanosteosarcomametastasisandprogressionbydirectlytargetingcdh6
AT xuyameng mir2233pinhibitshumanosteosarcomametastasisandprogressionbydirectlytargetingcdh6
AT taiyanhong mir2233pinhibitshumanosteosarcomametastasisandprogressionbydirectlytargetingcdh6
AT goodmanstuartb mir2233pinhibitshumanosteosarcomametastasisandprogressionbydirectlytargetingcdh6
AT biwenzhi mir2233pinhibitshumanosteosarcomametastasisandprogressionbydirectlytargetingcdh6
AT xumeng mir2233pinhibitshumanosteosarcomametastasisandprogressionbydirectlytargetingcdh6
AT jiaoshunchang mir2233pinhibitshumanosteosarcomametastasisandprogressionbydirectlytargetingcdh6
AT maloneywilliamj mir2233pinhibitshumanosteosarcomametastasisandprogressionbydirectlytargetingcdh6
AT wangyan mir2233pinhibitshumanosteosarcomametastasisandprogressionbydirectlytargetingcdh6